Advertisement

Tositumomab

  • Giuseppe Tridente
Chapter

Abstract

Tositumomab (Bexxar®, Corixa, GSK) is a murine IgGλ2a monoclonal antibody directed to the CD20 antigen expressed by normal and primate B lymphocytes, and on human malignant B cells. In the therapeutic regimen it is usually associated with tositumomab-Iodine131 to exert anti-neoplastic radioimmunotherapeutic effects.

Keywords

Lipid Raft Mantle Cell Lymphoma Orphan Designation Dendritic Reticulum Cell Murine IgG2a 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_37_MOESM1_ESM.xls (58 kb)
Supplementary material 1 (XLS 59 kb)

References

  1. 1.
    Tositumomab (Bexxar®) BLA 125011 Medical Review FDA, June 2003Google Scholar
  2. 2.
    Tositumomab (Bexxar®) BLA 125011/S024 Medical Review Dec 2004Google Scholar
  3. 3.
    Tositumomab (Bexxar®) Product Monograph GSK, Canada Dec 2007Google Scholar
  4. 4.
    Tositumomab (Bexxar®) Prescribing Information GSK, Aug 2012Google Scholar
  5. 5.
    Boross P, Leusen JHW (2012) Mechanisms of action of anti CD20 antibodies. Am J Cancer Res 2:676–690PubMedGoogle Scholar
  6. 6.
    Lim SH, Vaughan AT, Ashton-Key M et al (2011) Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118:2530–2540PubMedCrossRefGoogle Scholar
  7. 7.
    Buchegger F, Antonescu C, Helg C et al (2011) Six of twelve relapsed or refractory indolent lymphoma patients treated 10 years ago with 131Iodine-tositumomab remain in complete remission. J Nucl Med 52:896–900PubMedCrossRefGoogle Scholar
  8. 8.
    Link BK, Martin P, Kaminski SJ et al (2010) Cyclophosphamide, vincristine, and prednisone followed by tositumomab and Iodine-131–tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol 28:3035–3041PubMedCrossRefGoogle Scholar
  9. 9.
    Hattori N, Gopal AK, Shields AT et al (2012) 131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin’s lymphoma: radiation dose to the testes. Nuclear Med 33:1225–1231CrossRefGoogle Scholar
  10. 10.
    Press OW, Unger JM, Rimsza LM et al (2012) Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131Iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. doi: 10.1200/JCO.2012.42.4101 Google Scholar
  11. 11.
    Smith K, Byer G, Morris CG et al (2012) Outcomes of patients with non-Hodgkin’s lymphoma treated with Bexxar with or without external-beam radiotherapy. Int J Radiat Oncol Biol Phys 82:1122–1127PubMedCrossRefGoogle Scholar
  12. 12.
    Tositumomab (Bexxar®) Briefing Package for ODAC Meeting, GSK February 2011 Google Scholar
  13. 13.
    Persky DO, Dornan D, Goldman B et al (2012) Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 97(6):937–942 doi: 10.3324/haematol.2011.050419 Google Scholar
  14. 14.
    Hammadi M, Youinou P, Tempescul A et al (2011) Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells. Haematologica 96(3):400–407 doi: 10.3324/haematol.2011.051938 Google Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations